|
|
Volumn 5, Issue 2, 2003, Pages 79-80
|
|
Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: Ten years of successful antivascular therapy
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DACTINOMYCIN;
DOXORUBICIN;
GAMMA INTERFERON;
MELPHALAN;
TUMOR NECROSIS FACTOR;
ANGIOGENESIS INHIBITOR;
ANTINEOPLASTIC AGENT;
TUMOR NECROSIS FACTOR ALPHA;
ANGIOGRAPHY;
ANTINEOPLASTIC ACTIVITY;
APOPTOSIS;
CANCER GRADING;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG MEGADOSE;
DRUG POTENTIATION;
DRUG RESPONSE;
DRUG TARGETING;
HUMAN;
HYPOTENSION;
LIMB AMPUTATION;
LIMB PERFUSION;
MELANOMA;
NONHUMAN;
NOTE;
SOFT TISSUE SARCOMA;
TUMOR VASCULARIZATION;
CLINICAL TRIAL;
LIMB;
LIMB SALVAGE;
METHODOLOGY;
MULTICENTER STUDY;
NEOVASCULARIZATION (PATHOLOGY);
REGIONAL PERFUSION;
REVIEW;
SARCOMA;
SKIN TUMOR;
SOFT TISSUE TUMOR;
TREATMENT OUTCOME;
ANGIOGENESIS INHIBITORS;
ANTINEOPLASTIC AGENTS;
CHEMOTHERAPY, CANCER, REGIONAL PERFUSION;
CLINICAL TRIALS;
EXTREMITIES;
HUMANS;
LIMB SALVAGE;
MELANOMA;
MELPHALAN;
MULTICENTER STUDIES;
NEOVASCULARIZATION, PATHOLOGIC;
SARCOMA;
SKIN NEOPLASMS;
SOFT TISSUE NEOPLASMS;
TREATMENT OUTCOME;
TUMOR NECROSIS FACTOR-ALPHA;
|
|
EID: 0642316401
PISSN: 15233790
EISSN: None
Source Type: Journal
DOI: 10.1007/s11912-003-0091-x Document Type: Note |
|
Times cited : (23)
|
|
References (7)
|
